Add BrightSurf on Google Email

Impact Journals LLC


Metformin's role in preventing metabolic syndrome during androgen deprivation therapy: a Phase II study

A randomized phase II study found that adding metformin to androgen deprivation therapy did not reduce the risk of metabolic syndrome or improve PSA response in patients with advanced prostate cancer. Metformin showed some antitumor effects through mTOR inhibition, but these were not significant.

SourceImpact Journals LLC·JournalOncotarget·TypeRandomized controlled/clinical trial·DateJun 20, 2023

Precious1GPT: multimodal transfer learning for aging clock development and target discovery

Researchers developed Precious1GPT, a multimodal transformer-based approach for aging clock development and feature importance analysis. The model utilizes methylation and transcriptomic data to predict biological age and identify disease-related genes, providing a pathway for therapeutic drug discovery.

SourceImpact Journals LLC·JournalAging-US·TypeRandomized controlled/clinical trial·DateJun 20, 2023

Targeting the Src N-Terminal regulatory element in cancer

Researchers from Universitat de Barcelona and Universitat Internacional de Catalunya discuss the non-receptor protein tyrosine kinase Src as a good example of an oncogene. Targeting the Src N-terminal regulatory element (SNRE) has potential as oncotargets to inhibit Src activity only in cancer cells.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateJun 9, 2023

The aging mouse prostate: kinetics of lymphocyte infiltration

Researchers tracked immune cell clusters in the aging mouse prostate using highly multiplexed immune profiling. Early adulthood sees myeloid cells, while between 6-12 months old, there's a profound shift to T and B lymphocyte-dominance. The study reveals new insight into prostatic inflammaging and the window for interventions.

SourceImpact Journals LLC·JournalAging-US·TypeComputational simulation/modeling·DateMay 23, 2023

Automated, accurate reporting for NGS-based clonality testing

Researchers have developed an automated calling algorithm for determining B and T cell clonality from NGS data with greater sensitivity than previous models. The new model increases the assay's sensitivity in detecting clonality, allowing for more accurate diagnosis and monitoring of lymphoproliferative disorders.

SourceImpact Journals LLC·JournalOncotarget·TypeData/statistical analysis·DateMay 16, 2023

Systemic AL amyloidosis: Current approach and future direction

Researchers review current treatment updates for systemic light chain (AL) amyloidosis, highlighting the need for early diagnosis and effective maintenance therapy. The article discusses the relationship between AL amyloidosis and monoclonal gammopathy of undetermined significance (MGUS), emphasizing the importance of regular monitoring.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateMay 5, 2023

Cancer prevention with rapamycin

Researchers discuss rapamycin's potential to delay cancer onset by slowing cell proliferation and tumor progression. The mTOR pathway is involved in both cancer and aging, making rapamycin a promising chemopreventive agent.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateApr 17, 2023